Page last updated: 2024-08-18

quinuclidines and fluticasone propionate, salmeterol xinafoate drug combination

quinuclidines has been researched along with fluticasone propionate, salmeterol xinafoate drug combination in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (66.67)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
Neffen, H; Rodrigo, GJ	1
Church, A; Hardaker, L; Singh, D; Worsley, S; Zhu, CQ	1
Brooks, J; Church, A; Kerwin, E; Siler, TM; Singletary, K	1
Compton, C; Lipson, DA; Naya, IP; Tombs, L	1
Elliott, C; Essoi, B; Goolsby Hunter, A; Hahn, B; Moretz, C; Ray, R; White, J	1
Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT	1

Reviews

1 review(s) available for quinuclidines and fluticasone propionate, salmeterol xinafoate drug combination

Article	Year
A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD. Chest, 2015, Volume: 148, Issue:2 Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome	2015

Article

Year

A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD.

Chest, 2015, Volume: 148, Issue:2

Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Benzyl Alcohols; Chlorobenzenes; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome

2015

Trials

2 trial(s) available for quinuclidines and fluticasone propionate, salmeterol xinafoate drug combination

Article	Year
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC pulmonary medicine, 2015, Aug-19, Volume: 15 Topics: Administration, Inhalation; Adult; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome	2015
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD, 2016, Volume: 13, Issue:1 Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; Vital Capacity	2016

Article

Year

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.

BMC pulmonary medicine, 2015, Aug-19, Volume: 15

Topics: Administration, Inhalation; Adult; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome

2015

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.

COPD, 2016, Volume: 13, Issue:1

Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; Vital Capacity

2016

Other Studies

3 other study(ies) available for quinuclidines and fluticasone propionate, salmeterol xinafoate drug combination

Article	Year
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β Advances in therapy, 2018, Volume: 35, Issue:10 Topics: Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Respiratory System Agents; Secondary Prevention; Symptom Assessment; Treatment Outcome	2018
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. International journal of chronic obstructive pulmonary disease, 2020, Volume: 15 Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Sectional Studies; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Humans; Medicare Part C; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome; United States	2020
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β Chest, 2021, Volume: 160, Issue:4 Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines	2021